Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2025)

Vivos Therapeutics has reported Other Operating Expenses over the past 6 years, most recently at -$5.8 million for Q4 2025.

  • Quarterly Other Operating Expenses fell 71.11% to -$5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.8 million through Dec 2025, down 42.86% year-over-year, with the annual reading at -$21.2 million for FY2025, 77.65% down from the prior year.
  • Other Operating Expenses was -$5.8 million for Q4 2025 at Vivos Therapeutics, down from -$5.5 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $2.3 million in Q4 2021 and troughed at -$5.8 million in Q4 2025.
  • The 5-year median for Other Operating Expenses is $664500.0 (2023), against an average of -$220229.8.
  • Year-over-year, Other Operating Expenses skyrocketed 361.36% in 2021 and then tumbled 708.65% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $2.3 million in 2021, then tumbled by 46.69% to $1.2 million in 2022, then tumbled by 54.66% to $555000.0 in 2023, then crashed by 708.65% to -$3.4 million in 2024, then crashed by 71.11% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Operating Expenses are -$5.8 million (Q4 2025), -$5.5 million (Q3 2025), and $100000.0 (Q2 2025).